Johnson & Johnson is assuming full responsibility for the manufacturing of a drug substance for its Covid-19 vaccine at Emergent BioSolutions Inc.’s Bayview facility, the company said in a statement.

It will add dedicated leaders for operations and quality, and “significantly” increase the number of manufacturing, quality and technical operations personnel at the site, according to the statement.

• Orient Cables Eyes Rs 3,500 Crore Revenue By FY30
• Bangladesh Resumes Indian Wheat Purchases as Black Sea Disruptions Lift Prices
• Central Railway Recovers Rs 140 Crore In Ticket Fines
• Cosmic CRF Unit Bags Rs 25.94 Crore Combined Orders
• Arivihan in Talks to Raise Rs 96 Crore at Rs 570 Crore Valuation

The company will work closely with the Food and Drug Administration for the emergency use authorization of the specific facility, adding that all its doses so far have met regulatory quality standards. The company said it expects to deliver almost 100 million doses of the Covid-19 vaccine to the US government by the end of May.